Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Licenses Microarray Technology to PathWork for Cancer Dx

NEW YORK, Nov. 1 (GenomeWeb News) - Affymetrix has granted PathWork Informatics long-term non-exclusive access to its microarray technology to develop and market in vitro diagnostics for cancer.


Under the terms of the agreement, PathWork has the right to use Affymetrix's technology to develop tests for tumors of unknown origin, as well as other cancer tests, Affy said. PathWork will incorporate Affymetrix arrays into PathWorks Oncology Suites, the company's diagnostic kits that are currently under development.


Financial terms of the agreement were not disclosed.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.